Delving into the Latest Updates on Gifu Pharmaceutical University with Synapse

概览

疾病领域	数量

神经系统疾病	2

排名前五的药物类型	数量

小分子化药	1
细胞疗法	1
造影剂	1

排名前五的靶点	数量

CK2(酪蛋白激酶 II)	1

关联

7

项与 Gifu Pharmaceutical University 相关的药物

[11C]GO289

靶点

CK2

作用机制

CK2抑制剂

在研机构

Gifu Pharmaceutical University

原研机构

Gifu Pharmaceutical University

在研适应症

阿尔茨海默症

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

GCT-102

靶点-

作用机制-

在研机构

Gifu Pharmaceutical University [+4]

原研机构

Kidswell Bio Corp.

在研适应症

脑瘫 [+4]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

KYN-54

靶点-

作用机制-

在研机构-

原研机构

Kuraray Co., Ltd.

在研适应症-

非在研适应症

口腔肿瘤

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

13

项与 Gifu Pharmaceutical University 相关的临床试验

JPRN-UMIN000054268

/ SuspendedN/AIIT

A study of the relationship between plasma concentrations of linezolid and its relationship with the frequency of adverse events and discontinuation factors. - A study of the relationship between plasma concentrations of linezolid and its relationship with the frequency of adverse events and discontinuation factors.

开始日期2024-06-01

申办/合作机构

Gifu Pharmaceutical University

JPRN-UMIN000052478

/ RecruitingN/AIIT

Studies on the relationship between plasma concentrations of linezolid and its efficacy and thrombocytopenia - Studies on the relationship between plasma concentrations of linezolid and its efficacy and thrombocytopenia

开始日期2023-09-25

申办/合作机构

Gifu Pharmaceutical University

JPRN-UMIN000042868

/ CompletedN/AIIT

A Clinical Study of the Effects of Anxiety and Treatment Side Effects on Quality of Life in Patients with Malignant Lymphoma - A Clinical Study of the Effects of Anxiety and Treatment Side Effects on Quality of Life in Patients with Malignant Lymphoma

开始日期2021-01-01

申办/合作机构

Gifu Pharmaceutical University

100 项与 Gifu Pharmaceutical University 相关的临床结果

登录后查看更多信息

0 项与 Gifu Pharmaceutical University 相关的专利（医药）

登录后查看更多信息

5,315

项与 Gifu Pharmaceutical University 相关的文献（医药）

2025-06-01·European Journal of Pharmaceutics and Biopharmaceutics

Development of mucoadhesive films with high polaprezinc content for oral mucositis: A study on formulation and near-infrared spectroscopy-based quality control

Article

作者: Tahara, Kohei ; Yamazoe, Eriko ; Ito, Takaaki ; Ito, Takuya ; Suzuki, Akio ; Funato, Miyui

Polaprezinc (PLZ) has drawn attention to its potential to prevent oral mucositis caused by chemotherapy and radiotherapy. PLZ-containing lozenges have been developed in previous reports; however, for patients with mucositis, taking them may be challenging because of pain. Therefore, this study aimed to develop a mucoadhesive film containing the same amount (18.75 mg) of PLZ as a lozenge as a new dosage form to replace lozenges and evaluate its characteristics. First, various films were created using solvent casting to screen polymers with high PLZ content. Thus, hydroxypropyl cellulose (HPC) was selected; however, film curvature and reduced flexibility necessitated formulation optimization. The optimized films exhibited excellent content uniformity, stability, and mucoadhesive properties, with no significant changes in the drug content after storage. Furthermore, the possibility of using portable near-infrared spectroscopy (Micro NIR™) for the quality control of PLZ films was investigated. Multivariate analysis revealed that the Micro NIR calibration model predicted drug concentrations comparable to those measured by high-performance liquid chromatography. These results suggest that a mucoadhesive film with high PLZ content has been developed and that efficient quality control is possible using Micro NIR™.

2025-06-01·Molecular Therapy Methods & Clinical Development

Engineered ACE2 decoy in dry powder form for inhalation: A novel therapy for SARS-CoV-2 variants

Article

作者: Nishioka, Keisuke ; Itoh, Yumi ; Suzuki, Tatsuya ; Kanda, Yasunari ; Ito, Takaaki ; Sakai, Yusuke ; Ikemura, Nariko ; Matoba, Satoaki ; Sakamoto, Kentarou ; Takagi, Junichi ; Hoshino, Atsushi ; Tahara, Kohei ; Okamoto, Toru

The persistent threat of SARS-CoV-2 and the emergence of new variants has prompted the development of a novel, easily administered modality that can overcome viral mutations. The engineered ACE2 decoy shows neutralizing activity comparable to monoclonal antibodies and is broadly effective against SARS-CoV-2 variants and ACE2-utilizing sarbecoviruses. In addition to intravenous administration, this decoy has shown antiviral efficacy through nebulized aerosol inhalation in murine and primate models, offering a dose-sparing advantage. Clinically, dry powder formulation is ideal for convenience and storage but poses challenges for protein biologics. This study developed a freeze-dried spray formulation of the ACE2 decoy for inhalation. The trehalose and leucine-based excipient maintained neutralizing activity and prevented aggregate formation. The dry powder showed aerodynamic distribution from bronchi to alveoli, aiding protection against SARS-CoV-2 infections. Neutralizing activity, structural stability, and powder dispersibility were preserved after 6 months of storage. In a mouse model of SARS-CoV-2 infection, significant reductions in viral replication and lung pathology were observed with intratracheal administration 24 h post-infection. The ACE2 decoy retained activity against recent JN.1 and current KP.3 strains, confirming its robust efficacy against viral mutations. This ACE2 decoy powder inhalant is a self-administered, next-generation treatment addressing the ongoing immune-evading evolution of SARS-CoV-2.

2025-05-01·Experimental Cell Research

Type III sodium-dependent inorganic phosphate transporters are required for the phenotypes in human brain microvascular endothelial cells

Article

作者: Murata, Junya ; Ohuchi, Kazuki ; Izutsu, Mutsuko ; Mishima, Ayane ; Inden, Masatoshi ; Hayashi, Yuichi ; Watanabe, Ku ; Kurita, Hisaka ; Hozumi, Isao

Inorganic phosphate (Pi) homeostasis in the brain is critical for the development of primary brain calcification (PBC). In the brains of patients with PBC, calcification occurs in the cerebral small vessels, and it is primarily caused by mutated SLC20A2, a gene that encodes a type III Pi transporter. A previous study founded that the SLC20 family, which includes SLC20A1 and SLC20A2, contributes to Pi homeostasis in the central nervous system. However, the impact of these Pi transporters on the brain vessel phenotype remains unknown. Thus, in this study, we aimed to investigate the effect of SLC20A1 or SLC20A2 depletion on the phenotype of human brain microvascular endothelial cells (hBMECs). We assessed the primary phenotypes of vascular endothelial cells, such as proliferation, tube formation, and VE-cadherin expression. The results showed that hBMECs silenced for SLC20A1 or SLC20A2 had decreased proliferative and angiogenic ability, as well as VE-cadherin expression. The intracellular Pi concentration ([Pi]_i) remained constant in SLC20A1-silenced hBMECs whereas it increased in SLC20A2-silenced cells. Tube formation ability was no change even at 3 mM, a concentration higher than [Pi]_i which was increased in SLC20A2-silenced hBMECs. Thus, increased [Pi]_i in SLC20A2-silenced hBMECs may have a small impact on phenotypic changes. In conclusion, abnormalities in Pi homeostasis caused by SLC20A2 depletion were suggested to play a minor role in PBC endothelial pathology.

100 项与 Gifu Pharmaceutical University 相关的药物交易

登录后查看更多信息

100 项与 Gifu Pharmaceutical University 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年06月07日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

2

5

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

[11C]GO289 ( CK2 )	阿尔茨海默症更多	临床前
GCT-102	眼部疾病更多	临床前
KYN-54	口腔肿瘤更多	终止
FA-103 ( Bacterial DNA gyrase )	细菌感染更多	无进展
UK-21	肿瘤更多	无进展